Verified Nov 2026
Other
·
Brisbane, California
·
Since 2017
Mammoth Biosciences is a biotechnology company headquartered in Brisbane, California, founded in 2017 and employing roughly 100 to 200 people, with an estimated revenue band of $10 to $50 million. It is privately held. The company develops in vivo gene editing therapeutics and point-of-care diagnostics using ultracompact CRISPR systems, and serves healthcare, agriculture, environmental monitoring, and biodefense. In June 2026 it announced a partnership with M42 and the Abu Dhabi Department of Health to advance gene-editing drug development.
Mammoth Biosciences at a glance
Revenue
$10-50M
Est. band
Employees
100-200
Founded
2017
Headquarters
Brisbane, California
Industries
Automotive
Electric Vehicles
Medical
Military & Defense
Overview
Mammoth Biosciences is a biotechnology company headquartered in Brisbane, California, founded in 2017 and employing roughly 100 to 200 people, with an estimated revenue band of $10 to $50 million. It is privately held. The company develops in vivo gene editing therapeutics and point-of-care diagnostics using ultracompact CRISPR systems, and serves healthcare, agriculture, environmental monitoring, and biodefense. In June 2026 it announced a partnership with M42 and the Abu Dhabi Department of Health to advance gene-editing drug development.
At a glance
Attribute | Detail |
|---|---|
Founded | 2017 |
Headquarters | Brisbane, California |
Employees | 100-200 |
Revenue | $10-50M (estimated) |
What Mammoth Biosciences makes
Its platform includes proprietary ultracompact CRISPR systems, smaller than traditional Cas9 enzymes, along with base and epigenetic editing modalities and a CRISPR-based detection platform.
Latest developments
2026-10-28 — M42’s iROS and Mammoth Biosciences to Trial Gene Editing Therapy (m42.ae)
2026-06-25 — DoH, M42 & Mammoth Partner to Advance Gene-Editing Therapies (m42.ae)
2026-06-24 — Mammoth Biosciences to Partner With M42, Abu Dhabi Department of Health on Drug Development | GenomeWeb (genomeweb.com)
2025-11-21 — Watch Mammoth Biosciences CEO on Business Outlook - Bloomberg (bloomberg.com)
2025-10-09 — Mammoth Biosciences plans first trial of triglyceride-lowering gene editing therapy (endpoints.news)
2025-09-09 — VedaBio — Staging/Redesign (vedabio.com)
Company details
The company is privately held and, according to its reported profile, partners with pharmaceutical and biotechnology firms; its reported employee count is 100 to 200. Mammoth Biosciences was founded in 2017, has an estimated 100-200 employees, and is headquartered in Brisbane, California.
Frequently asked questions
What does Mammoth Biosciences do?
Mammoth Biosciences is a biotechnology company headquartered in Brisbane, California, founded in 2017 and employing roughly 100 to 200 people, with an estimated revenue band of $10 to $50 million. It is privately held. The company develops in vivo gene editing therapeutics and point-of-care diagnostics using ultracompact CRISPR systems, and serves healthcare, agriculture, environmental monitoring, and biodefense. In June 2026 it announced a partnership with M42 and the Abu Dhabi Department of Health to advance gene-editing drug development.
Where is Mammoth Biosciences headquartered?
Mammoth Biosciences is headquartered in Brisbane, California (1000 Marina Blvd, Brisbane, California, 94005-1800).
When was Mammoth Biosciences founded?
Mammoth Biosciences was founded in 2017.
How big is Mammoth Biosciences?
Mammoth Biosciences has an estimated 100-200 employees, with revenue in the $10-50M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.